HCW Biologics Inc. (HCWB)

NASDAQ: HCWB · IEX Real-Time Price · USD
1.500
-0.100 (-6.25%)
Apr 17, 2024, 1:54 PM EDT - Market open
-6.25%
Market Cap 59.38M
Revenue (ttm) 560,360
Net Income (ttm) -24.99M
Shares Out 37.82M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,407
Open 1.530
Previous Close 1.600
Day's Range 1.500 - 1.570
52-Week Range 0.910 - 2.320
Beta 0.98
Analysts Strong Buy
Price Target 9.00 (+500.0%)
Earnings Date May 7, 2024

About HCWB

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2021
Employees 45
Stock Exchange NASDAQ
Ticker Symbol HCWB
Full Company Profile

Financial Performance

In 2023, HCW Biologics's revenue was $560,360, a decrease of -78.33% compared to the previous year's $2.59 million. Losses were -$24.99 million, 67.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for HCWB stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 500.00% from the latest price.

Price Target
$9.0
(500.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...

15 days ago - GlobeNewsWire

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

5 months ago - GlobeNewsWire

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable ...

5 months ago - GlobeNewsWire

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

6 months ago - GlobeNewsWire

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update f...

8 months ago - GlobeNewsWire

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

8 months ago - GlobeNewsWire

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with Cancer Allowed Methods of Use Claims Direc...

11 months ago - GlobeNewsWire

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing n...

1 year ago - GlobeNewsWire

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Compan...

1 year ago - GlobeNewsWire

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE NEWSWIRE...

1 year ago - GlobeNewsWire

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Published a Pivotal Scientific Paper in Aging Cell

1 year ago - GlobeNewsWire

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...

1 year ago - GlobeNewsWire

HCW Biologics Enters CRADA with National Cancer Institute

NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advan...

1 year ago - GlobeNewsWire

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Allowed Claims for Novel Immunotherapeutic Compound  Constructed with Tissue Factor as Platform for Target Binding Domains

1 year ago - GlobeNewsWire

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

1 year ago - GlobeNewsWire

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: SMSI
1 year ago - Benzinga

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: CASIHSDT
1 year ago - Benzinga

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

1 year ago - GlobeNewsWire

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Produ...

1 year ago - GlobeNewsWire

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapie...

2 years ago - GlobeNewsWire

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunother...

2 years ago - GlobeNewsWire

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells  Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy

2 years ago - GlobeNewsWire

HCW Biologics' CEO Hing C. Wong, Ph.D.

Preclinical data for lead investigational drug, HCW9218,  in treatment of therapy-induced senescence in cancer

2 years ago - GlobeNewsWire

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023

2 years ago - GlobeNewsWire